胎盘来源细胞疗法治疗新型冠状病毒肺炎所致呼吸衰竭患者
该回顾性病例报告纳入2020年3月26日至4月4日在以色列4家医院及美国新泽西州Holy Name医疗中心治疗的8例新型冠状病毒肺炎相关急性呼吸窘迫综合征有创机械通气危重患者,接受胎盘扩展细胞(PLX-PAD)300×10^6个细胞肌内注射1至2次,随访至治疗后第17天。至随访终点5例出院、2例仍在住院、1例死亡;注射后第3天C反应蛋白平均下降45%(240.3降至131.3 mg/L,p=0.0019),第5天下降77%(56.0 mg/L,p<0.0001);5/8例患者治疗后24小时PaO2/FiO2改善,48小时效果相似;第0至14天呼气末正压下降(p=0.0032)和pH升高(p=0.00072)有统计学意义。作者认为上述改善提示可能疗效,但受样本量小、联合使用研究性治疗及无对照设计限制,PLX-PAD在新型冠状病毒肺炎中的疗效需在对照临床试验中进一步评估。
要点
- 8例新型冠状病毒肺炎相关急性呼吸窘迫综合征有创通气患者接受PLX-PAD 300×10^6个细胞肌内注射1至2次,5例出院、2例仍住院、1例死亡。
- 注射后第3天C反应蛋白平均下降45%(240.3降至131.3 mg/L,p=0.0019),第5天下降77%(56.0 mg/L,p<0.0001)。
- 5/8例患者治疗后24小时PaO2/FiO2改善,48小时效果相似;第0至14天呼气末正压下降(p=0.0032)、pH升高(p=0.00072)有统计学意义。
- 第0至5天及第0至14天血红蛋白下降有统计学意义(p=0.015和p=0.0028),第0至14天肌酐下降有统计学意义(p=0.032)。
- 作者认为上述改善提示可能疗效,但受样本量小、联合使用研究性治疗及无对照设计限制,需在对照临床试验中进一步评估。
适用人群与场景
- 新型冠状病毒肺炎所致急性呼吸窘迫综合征、接受有创机械通气的危重患者,共8例(中位年龄55岁,男7例、女1例)。
处置流程与药物剂量
- PLX-PAD(Pluristem Therapeutics,海法,以色列)300×10^6个细胞,肌内注射,给予1至2次治疗。
研究设计与关键结果
- 回顾性病例报告,8例新型冠状病毒肺炎相关急性呼吸窘迫综合征有创通气患者,2020年3月26日至4月4日接受PLX-PAD治疗,随访至2020年5月2日;至治疗后第17天5例出院、2例仍住院、1例死亡。
- 注射后第3天C反应蛋白平均下降45%(240.3降至131.3 mg/L,p=0.0019),第5天下降77%(56.0 mg/L,p<0.0001)。
- 5/8例患者治疗后24小时PaO2/FiO2改善,48小时效果相似;第0至14天呼气末正压下降(p=0.0032)、pH升高(p=0.00072)有统计学意义。
- 第0至5天及第0至14天血红蛋白下降有统计学意义(p=0.015和p=0.0028),第0至14天肌酐下降有统计学意义(p=0.032)。
证据类型、等级与局限
- 证据类型:回顾性病例报告。
- 局限:样本量小;联合使用研究性治疗;无对照研究设计;作者结论为PLX-PAD在新型冠状病毒肺炎中的疗效需在对照临床试验中进一步评估。
对床旁实践的改变
- 作者认为PLX-PAD治疗后观察到C反应蛋白、呼气末正压和PaO2/FiO2等指标改善,提示可能疗效;但受样本量小、联合使用研究性治疗及无对照设计限制,需在对照临床试验中进一步评估。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To determine whether placental cell therapy PLacental eXpanded (PLX)-PAD (Pluristem Therapeutics, Haifa, Israel) may be beneficial to treating critically ill patients suffering from acute respiratory distress syndrome due to coronavirus disease 2019.
DESIGN: Retrospective case report of critically ill coronavirus disease 2019 patients treated with PLacental eXpanded (PLX)-PAD from March 26, 2020, to April 4, 2020, with follow-up through May 2, 2020.
SETTING: Four hospitals in Israel (Rambam Health Care Campus, Bnai Zion Medical Center, and Samson Assuta Ashdod University Hospital), and Holy Name Medical Center in New Jersey.
PATIENTS: Eight critically ill patients on invasive mechanical ventilation, suffering from acute respiratory distress syndrome due to coronavirus disease 2019.
INTERVENTIONS: Intramuscular injection of PLacental eXpanded (PLX)-PAD (300 × 106 cells) given as one to two treatments.
MEASUREMENTS AND MAIN RESULTS: Mortality, time to discharge, and changes in blood and respiratory variables were monitored during hospitalization to day 17 posttreatment. Of the eight patients treated (median age 55 yr, seven males and one female), five were discharged, two remained hospitalized, and one died. By day 3 postinjection, mean C-reactive protein fell 45% (240.3-131.3 mg/L; p = 0.0019) and fell to 77% by day 5 (56.0 mg/L; p < 0.0001). Pao2/Fio2 improved in 5:8 patients after 24-hour posttreatment, with similar effects 48-hour posttreatment. A decrease in positive end-expiratory pressure and increase in pH were statistically significant between days 0 and 14 (p = 0.0032 and p = 0.00072, respectively). A decrease in hemoglobin was statistically significant for days 0-5 and 0-14 (p = 0.015 and p = 0.0028, respectively), whereas for creatinine, it was statistically significant between days 0 and 14 (p = 0.032).
CONCLUSIONS: Improvement in several variables such as C-reactive protein, positive end-expiratory pressure, and Pao2/Fio2 was observed following PLacental eXpanded (PLX)-PAD treatment, suggesting possible therapeutic effect. However, interpretation of the data is limited due to the small sample size, use of concomitant investigational therapies, and the uncontrolled study design. The efficacy of PLacental eXpanded (PLX)-PAD in coronavirus disease 2019 should be further evaluated in a controlled clinical trial.
参考来源
- Barkama R, Mayo A, Paz A, et al. Placenta-Derived Cell Therapy to Treat Patients With Respiratory Failure Due to Coronavirus Disease 2019. Crit Care Explor. 2020. PMID: 32984833. doi:10.1097/CCE.0000000000000207
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。